Text Size

Follow up of Autoantibodies in Active Tuberculosis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2007 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT00551226
First received: October 27, 2007
Last updated: October 29, 2007
Last verified: October 2007
History of Changes
  Purpose

We have previoulsy shown that patients with active Tuberculosis develop a wide array of autoantibodies including rheumatoid factor, anti-CCP, Antinuclear facyor and anti Sm antibodies. The purpose of this study is to evaluate whether the level of autoantibodies decrease after treatment aganist tuberculosis.


Condition
Tuberculosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Follow up of Autoantibodies in Active Tuberculosis

Resource links provided by NLM:

MedlinePlus related topics: Tuberculosis
U.S. FDA Resources

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • Follow up after levels of autoantibodies [ Time Frame: 1 year ]

Biospecimen Retention:   Samples Without DNA

Serum of patients


Estimated Enrollment: 50
Study Start Date: November 2007
Estimated Study Completion Date: November 2008
Groups/Cohorts
1
Patients with tuberculosis
2
Healthy controls

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients diagnosed with active tuberculosis who are currently receiving anti tuberculosis drugs

Criteria

Inclusion Criteria:

  • Active Tuberculosis treated

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00551226

Contacts
Contact: Ori Elkayam, M.D 97236973668 oribe14@netvision.net.il

Locations
Israel
Tel Aviv Medical Center Not yet recruiting
Tel Aviv, Israel, 64239
Contact: Ori Elkayam, M.D     97236973668     oribe14@netvision.net.il    
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Investigators
Principal Investigator: Ori Elkayam, M.D Tel Aviv Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00551226     History of Changes
Other Study ID Numbers: 314-07
Study First Received: October 27, 2007
Last Updated: October 29, 2007
Health Authority: Israel: Ministry of Health

Keywords provided by Tel-Aviv Sourasky Medical Center:
TB
Patients with tuberculosis

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
 Autoantibodies
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 21, 2013